Saccharo
Saccharo is a preclinical stage oncology company developing a pipeline of cancer therapies targeting a novel polysaccharide based immune shielding pathway. Their mission is to develop innovative cancer treatments by targeting the unique polysaccharide molecule dPSA, which is re-expressed on cancer cells and associated with nucleolin, offering a potentially more specific and effective therapeutic approach.
Industries
biotechnology
medical
oncology
therapeutics
Nr. of Employees
small (1-50)
Products
Antibody-based therapeutics targeting cancer-associated polysaccharide (dPSA)
Pipeline of high-affinity antibody lead candidates and a lead antibody–drug conjugate candidate directed at a cancer-associated polysaccharide for broad oncology applications.
Diagnostic screening assays for cancer-associated polysaccharide (dPSA)
Development of screening and diagnostic assays to detect dPSA for patient selection and potential companion diagnostic applications.
Antibody-based therapeutics targeting cancer-associated polysaccharide (dPSA)
Pipeline of high-affinity antibody lead candidates and a lead antibody–drug conjugate candidate directed at a cancer-associated polysaccharide for broad oncology applications.
Diagnostic screening assays for cancer-associated polysaccharide (dPSA)
Development of screening and diagnostic assays to detect dPSA for patient selection and potential companion diagnostic applications.
Expertise Areas
- Preclinical oncology drug development
- Antibody therapeutics and ADC development
- Glycan/polysaccharide biomarker discovery and validation
- Diagnostic assay development for biomarker screening
Key Technologies
- Glycan/polysaccharide biomarker discovery
- Antibody engineering
- Antibody–drug conjugation (ADC)
- Tissue expression profiling (IHC/histology)